AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38489346 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 390
Study 38489493 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Choice Intervention (DCP)
Number of subjects: 400
Study 38489493 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SEARCH)
Number of subjects: 400
Study 38489552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 240
Study 38489552 — intervention group
Group type: EXPERIMENTAL
Intervention: Myosteatosis
Number of subjects: 240
Study 38489552 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral obesity
Number of subjects: 240
Study 38489552 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative worsening sarcopenia
Number of subjects: 240
Study 38489552 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative worsening myosteatosis
Number of subjects: 240
Study 38489664 — intervention group
Group type: EXPERIMENTAL
Intervention: First-stage tissue expander (TE) insertion
Number of subjects: 1058
Study 38489664 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-stage TE exchange
Number of subjects: 1058
Study 38489664 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for infection after first-stage procedure
Number of subjects: 1058
Study 38489664 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for infection after second-stage procedure
Number of subjects: 1058
Study 38489664 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy
Number of subjects: 1058
Study 38489667 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention
Number of subjects: 603
Study 38489667 — intervention group
Group type: EXPERIMENTAL
Intervention: C allele
Number of subjects: 603
Study 38489858 — intervention group
Group type: EXPERIMENTAL
Intervention: dB+TopoCyclo (n=24)
Number of subjects: 39
Study 38489858 — intervention group
Group type: EXPERIMENTAL
Intervention: dB+TOTEM/TEMIRI (n=15)
Number of subjects: 39
Study 38490057 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (0.75 mg/m²) and Paclitaxel (TP)
Number of subjects: 0
Study 38490057 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (0.75 mg/m²) and Cisplatin (TC)
Number of subjects: 0
Study 38490057 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-containing arm
Number of subjects: 0
Study 38490057 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 0
Study 38490102 — intervention group
Group type: EXPERIMENTAL
Intervention: PeriCord (engineered tissue graft consisting of a decellularised pericardial matrix and umbilical cord Wharton's jelly mesenchymal stromal cells)
Number of subjects: 12
Study 38490102 — intervention group
Group type: EXPERIMENTAL
Intervention: PeriCord
Number of subjects: 12
Study 38490102 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study 38490230 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped collaborative care (once-weekly cognitive behavioural therapy for 50-60 min via telemedicine)
Number of subjects: 459
Study 38490230 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped collaborative care
Number of subjects: 459
Study 38490230 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (screening and referral to a health-care provider for treatment of symptoms)
Number of subjects: 459
Study 38490263 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored counseling and navigation (TCN)
Number of subjects: 0
Study 38490263 — intervention group
Group type: COMPARATOR
Intervention: Targeted print (TP)
Number of subjects: 0
Study 38490263 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 38490284 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (website + text messaging + additional features)
Number of subjects: 195
Study 38490284 — intervention group
Group type: COMPARATOR
Intervention: Original intervention (website only)
Number of subjects: 195
Study 38490532 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g/d prune
Number of subjects: 183
Study 38490532 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g/d prune
Number of subjects: 183
Study 38490532 — intervention group
Group type: COMPARATOR
Intervention: Control (no-prune)
Number of subjects: 183
Study 38490651 — intervention group
Group type: EXPERIMENTAL
Intervention: Local muscle vibrations (LMVs) at 80 Hz for the interventional group
Number of subjects: 100
Study 38490651 — intervention group
Group type: COMPARATOR
Intervention: Local muscle vibrations (LMVs) at 40 Hz plus a foam band for the control group
Number of subjects: 100
Study 38490660 — intervention group
Group type: EXPERIMENTAL
Intervention: LSALT peptide 5 mg intravenously daily for up to 14 days
Number of subjects: 61
Study 38490660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 38490668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus Low Disease Activity State (LLDAS) attainment
Number of subjects: 680
Study 38490668 — intervention group
Group type: COMPARATOR
Intervention: Non-LLDAS
Number of subjects: 680
Study 38490697 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI treat-to-target strategy
Number of subjects: 131
Study 38490697 — intervention group
Group type: COMPARATOR
Intervention: Conventional treat-to-target strategy
Number of subjects: 131
Study 38491111 — intervention group
Group type: EXPERIMENTAL
Intervention: Durable polymer drug-eluting stents (DP-DESs)
Number of subjects: 620
Study 38491111 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable polymer drug-eluting stents (BP-DESs)
Number of subjects: 620
Study 38491111 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DP-DES and BP-DES)
Number of subjects: 620
Study 38491141 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with sickle cell disease
Number of subjects: 72
Study 38491141 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 72
Study 38491190 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating apoM
Number of subjects: 182
Study 38491190 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 182
Study 38491190 — intervention group
Group type: COMPARATOR
Intervention: Surgery-induced slimming program
Number of subjects: 182
Study 38491260 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised HRVB
Number of subjects: 44
Study 38491260 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HRVB
Number of subjects: 44
Study 38491260 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 44
Study 38491303 — intervention group
Group type: EXPERIMENTAL
Intervention: Wim Hof Method with cold exposure (WHM-C)
Number of subjects: 60
Study 38491303 — intervention group
Group type: EXPERIMENTAL
Intervention: Wim Hof Method without cold exposure (WHM-NC)
Number of subjects: 60
Study 38491303 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 60
Study 38491303 — intervention group
Group type: EXPERIMENTAL
Intervention: Wim Hof Method (WHM-C and WHM-NC)
Number of subjects: 60
Study 38491364 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcome assessments (COAs)
Number of subjects: 188
Study 38491376 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based intervention (EBI; protocol-based hypertension treatment)
Number of subjects: 18
Study 38491376 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based collaborative care (implementation strategy)
Number of subjects: 18
Study 38491376 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptations planned amid COVID-19
Number of subjects: 18
Study 38491376 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative programmatic data analysis (July 2019-July 2021)
Number of subjects: 18
Study 38491376 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative thematic analysis
Number of subjects: 18
Study 38491429 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP < 1.0 mg/L
Number of subjects: 105
Study 38491429 — intervention group
Group type: COMPARATOR
Intervention: hs-CRP ≥ 1.0 mg/L
Number of subjects: 105
Study 38491429 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline large artery elasticity
Number of subjects: 105
Study 38491429 — intervention group
Group type: COMPARATOR
Intervention: Normal large artery elasticity
Number of subjects: 105
Study 38491429 — intervention group
Group type: COMPARATOR
Intervention: OxLDL
Number of subjects: 105
Study 38491460 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 0
Study 38491460 — intervention group
Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 0
Study 38491460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38491507 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard MAP (50-60 mmHg)
Number of subjects: 0
Study 38491507 — intervention group
Group type: EXPERIMENTAL
Intervention: High MAP (70-80 mmHg)
Number of subjects: 0
Study 38491507 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-tailored MAP (comparable to the patient's preoperative MAP)
Number of subjects: 0
Study 38491540 — intervention group
Group type: EXPERIMENTAL
Intervention: BBT-VR-HT
Number of subjects: 42
Study 38491540 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-MR
Number of subjects: 42
Study 38491540 — intervention group
Group type: EXPERIMENTAL
Intervention: BBT-VR-C
Number of subjects: 42
Study 38491540 — intervention group
Group type: EXPERIMENTAL
Intervention: BBT-MR
Number of subjects: 42
Study 38491546 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-paced breathing condition
Number of subjects: 0
Study 38491546 — intervention group
Group type: COMPARATOR
Intervention: random-paced breathing condition
Number of subjects: 0
Study 38491559 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based care (GBC)
Number of subjects: 92
Study 38491559 — intervention group
Group type: EXPERIMENTAL
Intervention: GBC plus nicotine metabolism-informed care (MIC)
Number of subjects: 92
Study 38491559 — intervention group
Group type: EXPERIMENTAL
Intervention: GBC plus counseling guided by a polygenic risk score (PRS) for lung cancer
Number of subjects: 92
Study 38491795 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 10/30 mg according to weight (<35/≥35 kg)
Number of subjects: 30
Study 38491795 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 30
Study 38491965 — intervention group
Group type: COMPARATOR
Intervention: Bed-Cycle
Number of subjects: 186
Study 38491965 — intervention group
Group type: COMPARATOR
Intervention: Book-Exe
Number of subjects: 186
Study 38491965 — intervention group
Group type: COMPARATOR
Intervention: SoC
Number of subjects: 186
Study 38491965 — intervention group
Group type: COMPARATOR
Intervention: Combined exercise (Bed-Cycle and Book-Exe)
Number of subjects: 186
Study 38492010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfate tablets (OST)
Number of subjects: 254
Study 38492010 — intervention group
Group type: COMPARATOR
Intervention: 2 L-polyethylene glycol/ascorbate (2 L-PEG/Asc)
Number of subjects: 254
Study 38492035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate users
Number of subjects: 27405
Study 38492035 — intervention group
Group type: COMPARATOR
Intervention: Nonusers
Number of subjects: 27405
Study 38492078 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme hypofractionated radiotherapy (RT) with concomitant boost to the dominant intraprostatic lesion (DIL)
Number of subjects: 65
Study 38492157 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib
Number of subjects: 0
Study 38492157 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab ± chemotherapy
Number of subjects: 0
Study 38492157 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel ± nintedanib
Number of subjects: 0
Study 38492506 — intervention group
Group type: EXPERIMENTAL
Intervention: Manually driven hysteroscopic tissue removal system
Number of subjects: 55
Study 38492506 — intervention group
Group type: COMPARATOR
Intervention: Motor driven hysteroscopic tissue removal system
Number of subjects: 55
Study 38492517 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the subthalamic nucleus (STN-DBS)
Number of subjects: 170
Study 38492517 — intervention group
Group type: COMPARATOR
Intervention: Medication therapy
Number of subjects: 170
Study 38492558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique stabilizers
Number of subjects: 30
Study 38492558 — intervention group
Group type: COMPARATOR
Intervention: Perpendicular stabilizers
Number of subjects: 30
Study 38492626 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 0
Study 38492626 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 0
Study 38492667 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive SARS-CoV-2 nasopharyngeal RT-PCR
Number of subjects: 2410
Study 38492667 — intervention group
Group type: COMPARATOR
Intervention: Negative serology or equivocal at delivery and no positive RT-PCR
Number of subjects: 2410
Study 38492765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature-based exercise
Number of subjects: 104
Study 38492765 — intervention group
Group type: COMPARATOR
Intervention: Indoor exercise
Number of subjects: 104
Study 38492765 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability measures
Number of subjects: 104
Study 38492903 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA 45 mg once daily (UPA45)
Number of subjects: 1021
Study 38492903 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1021
Study 38492904 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg (induction)
Number of subjects: 1021
Study 38492904 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg (maintenance)
Number of subjects: 1021
Study 38492904 — intervention group
Group type: COMPARATOR
Intervention: Placebo (induction and maintenance)
Number of subjects: 1021
Study 38493021 — intervention group
Group type: EXPERIMENTAL
Intervention: Avutometinib
Number of subjects: 3
Study 38493021 — intervention group
Group type: EXPERIMENTAL
Intervention: Avutometinib/VS-4718
Number of subjects: 3
Study 38493021 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3
Study 38493021 — intervention group
Group type: COMPARATOR
Intervention: VS-4718
Number of subjects: 3
Study 38493021 — intervention group
Group type: EXPERIMENTAL
Intervention: Avutometinib, FAK inhibitor defactinib, and their combination
Number of subjects: 3
Study 38493055 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents (n=281; 60%)
Number of subjects: 765
Study 38493055 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (n=118; 25%)
Number of subjects: 765
Study 38493055 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (52% of antibiotic-related reactions)
Number of subjects: 765
Study 38493055 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 765
Study 38493055 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 765
Study 38493055 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 765
Study 38493055 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 765
Study 38493088 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient therapy (not specified dosage or duration)
Number of subjects: 93
Study 38493088 — intervention group
Group type: COMPARATOR
Intervention: Current neonatal skincare practices (petroleum jelly application, cooking oil, and other natural oils)
Number of subjects: 93
Study 38493088 — intervention group
Group type: COMPARATOR
Intervention: Cultural norms and experiences of new mothers
Number of subjects: 93
Study 38493216 — intervention group
Group type: EXPERIMENTAL
Intervention: During the COVID-19 pandemic school closures, children with obesity experienced decreases in physical activity and sleep duration.
Number of subjects: 94
Study 38493216 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumption of in-person activities after school closures.
Number of subjects: 94
Study 38493287 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 462
Study 38493287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 462
Study 38493287 — intervention group
Group type: EXPERIMENTAL
Intervention: Short telomeres (TL < 20th percentile)
Number of subjects: 462
Study 38493348 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38493482 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative haploidentical bone marrow transplant (BMT) with thiotepa and posttransplant cyclophosphamide (PTCy)
Number of subjects: 70
Study 38493531 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with cardiogenic shock
Number of subjects: 772
Study 38493531 — intervention group
Group type: COMPARATOR
Intervention: Men with cardiogenic shock
Number of subjects: 772
Study 38493531 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sexes
Number of subjects: 772
Study 38493832 — intervention group
Group type: EXPERIMENTAL
Intervention: Aficamten 5-15 mg once daily for 10 weeks
Number of subjects: 41
Study 38493909 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 382
Study 38493909 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Steady State (MISS)
Number of subjects: 382
Study 38493953 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine oral suspension
Number of subjects: 50
Study 38493953 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 50
Study 38494157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dosing regimens of cefoxitin
Number of subjects: 123
Study 38494157 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of cefoxitin
Number of subjects: 123
Study 38494380 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen annihilation therapy (AAT; leuprolide, abiraterone acetate plus prednisone, and apalutamide) plus metastasis-directed stereotactic body radiotherapy (SBRT) for 6 months
Number of subjects: 28
Study 38494412 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-BN-WEV vaccine (2 doses, 4 weeks apart)
Number of subjects: 45
Study 38494493 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Micro Sclerotomy (MIMS) procedure
Number of subjects: 120
Study 38494525 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus clausii spore probiotics (LiveSpo CLAUSY; 2 billion CFU/5 mL ampoule) at high dosages of 4-6 ampoules a day
Number of subjects: 0
Study 38494525 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus clausii spore probiotics (LiveSpo CLAUSY)
Number of subjects: 0
Study 38494526 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE) after 3-month neo-adjuvant chemotherapy.
Number of subjects: 17
Study 38494571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg/day) with lifestyle education
Number of subjects: 240
Study 38494571 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle education alone
Number of subjects: 240
Study 38494574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (various doses)
Number of subjects: 0
Study 38494574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0
Study 38494574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0
Study 38494574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 0
Study 38494574 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 38494597 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus concurrent chemoradiotherapy (cCRT) with cisplatin
Number of subjects: 8
Study 38494847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AF82422 (75, 225, 750, 2250, 4500, and 9000 mg for cohorts A1-A6; 2250 and 9000 mg for cohorts B1 and B2)
Number of subjects: 0
Study 38494847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AF82422
Number of subjects: 0
Study 38494847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38495101 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38495115 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable UV dosimeter and UV counseling from a dermatologist
Number of subjects: 97
Study 38495115 — intervention group
Group type: COMPARATOR
Intervention: UV counseling from a dermatologist
Number of subjects: 97
Study 38495521 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended mobile-based lifestyle intervention
Number of subjects: 240
Study 38495521 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 38495608 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (AL) treatment (441mg, 662mg, or 882mg every 4 weeks or 882mg every 6 weeks) for six months
Number of subjects: 51
Study 38495608 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (AL) treatment
Number of subjects: 51
Study 38496180 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.25 mg/kg
Number of subjects: 13
Study 38496180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 38496316 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation training for four weeks
Number of subjects: 0
Study 38496316 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38496326 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch
Number of subjects: 41
Study 38496516 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine fibroids present
Number of subjects: 7030
Study 38496516 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine fibroids diagnosed based on ICD code (n=297)
Number of subjects: 7030
Study 38496516 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic incidental ultrasound diagnosis of uterine fibroids (n=192)
Number of subjects: 7030
Study 38496516 — intervention group
Group type: COMPARATOR
Intervention: Women without uterine fibroids
Number of subjects: 7030
Study 38496619 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib plus quercetin (senolytic treatment)
Number of subjects: 0
Study 38497150 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 94